[go: up one dir, main page]

MX2023012875A - 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef. - Google Patents

2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef.

Info

Publication number
MX2023012875A
MX2023012875A MX2023012875A MX2023012875A MX2023012875A MX 2023012875 A MX2023012875 A MX 2023012875A MX 2023012875 A MX2023012875 A MX 2023012875A MX 2023012875 A MX2023012875 A MX 2023012875A MX 2023012875 A MX2023012875 A MX 2023012875A
Authority
MX
Mexico
Prior art keywords
metabolic disease
hfpef
oxadiazol
thiazol
fluoroalkyl
Prior art date
Application number
MX2023012875A
Other languages
Spanish (es)
Inventor
Jin Yang
Timothy C Hoey
Mohammad A Mandegar
Original Assignee
Tenaya Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tenaya Therapeutics Inc filed Critical Tenaya Therapeutics Inc
Publication of MX2023012875A publication Critical patent/MX2023012875A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Provided herein are methods of treating or preventing metabolic disease with an HDAC6 inhibitor. Also provided herein are methods of treating or preventing heart failure with preserved ejection fraction with an HDAC6 inhibitor. A variety of HDAC6 inhibitors are described herein for use in treating or preventing metabolic disease or heart failure with preserved ejection fraction. In one aspect, described herein are methods of treating a human patient by orally administering an HDAC6 inhibitor, such as an inhibitor of Formula (I) or Formula (II).
MX2023012875A 2021-05-04 2022-05-04 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef. MX2023012875A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163183914P 2021-05-04 2021-05-04
US202163210676P 2021-06-15 2021-06-15
US202163210690P 2021-06-15 2021-06-15
PCT/US2022/027725 WO2022235842A1 (en) 2021-05-04 2022-05-04 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef

Publications (1)

Publication Number Publication Date
MX2023012875A true MX2023012875A (en) 2024-01-12

Family

ID=82100364

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012875A MX2023012875A (en) 2021-05-04 2022-05-04 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef.

Country Status (10)

Country Link
US (2) US20240252502A1 (en)
EP (1) EP4333841A1 (en)
JP (1) JP2024519499A (en)
KR (1) KR20240016950A (en)
AU (1) AU2022270657A1 (en)
CA (1) CA3216768A1 (en)
IL (1) IL308152A (en)
MX (1) MX2023012875A (en)
TW (1) TW202308619A (en)
WO (1) WO2022235842A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
KR20220119653A (en) 2019-12-20 2022-08-30 테나야 테라퓨틱스, 인코포레이티드 Fluoroalkyl-oxadiazoles and uses thereof
MX2023012875A (en) 2021-05-04 2024-01-12 Tenaya Therapeutics Inc 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef.
US20240139187A1 (en) * 2022-10-12 2024-05-02 The Children's Medical Center Corporation Selective hypothalamus permeable hdac6 inhibitors for treatment of leptin-resistant obesity
WO2025076457A1 (en) 2023-10-06 2025-04-10 Tenaya Therapeutics, Inc. Hdac6-selective inhibitor for use in the treatment of obesity, cardiovascular and metabolic diseases and disorders

Family Cites Families (188)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3187611B2 (en) 1993-05-17 2001-07-11 キヤノン株式会社 Liquid crystal compound, liquid crystal composition containing the same, liquid crystal element having the same, display method and display device using them
WO1997040017A2 (en) 1996-04-19 1997-10-30 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
EP0826685A1 (en) 1996-08-21 1998-03-04 Pfizer Inc. Stable, long acting salts of carboxamides for the treatment of joint disease
DE19744792A1 (en) 1997-10-10 1999-04-15 Hoechst Ag Triptycene derivatives for use in electroluminescent devices
ATE223210T1 (en) 1998-04-14 2002-09-15 Hisamitsu Pharmaceutical Co THE USE OF A GP IIB/IIIA ANTAGONIST FOR THE PRODUCTION OF A MEDICATION SUITABLE FOR TRANSDERMAL APPLICATION USING IONTOPHORESIS
DE69914931T2 (en) 1998-10-09 2004-12-16 Janssen Pharmaceutica N.V. 4,5-DEHYDROISOXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE
US6706686B2 (en) 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
AU2003217810C9 (en) 2002-02-28 2008-06-12 Icagen, Inc. Methods for treating diseases related to intraocular pressure
US7119112B2 (en) 2002-02-28 2006-10-10 Icagen, Inc. Sulfonamides as potassium channel blockers
US20050176686A1 (en) 2002-07-23 2005-08-11 4Sc Ag Novel compounds as histone deacetylase inhibitors
NZ541902A (en) 2003-02-07 2008-12-24 Janssen Pharmaceutica Nv Pyrimidine derivatives for the prevention of HIV infection
AU2004213173B2 (en) 2003-02-07 2010-07-29 Janssen Pharmaceutica N.V. HIV inhibiting 1,2,4-triazines
US20040167188A1 (en) 2003-02-14 2004-08-26 Zhili Xin Protein-tyrosine phosphatase inhibitors and uses thereof
US7169797B2 (en) 2003-02-14 2007-01-30 Abbott Laboratories Protein-tyrosine phosphatase inhibitors and uses thereof
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
JP2007223901A (en) 2004-03-24 2007-09-06 Takeda Chem Ind Ltd Heterocyclic compound and use thereof
GB0519957D0 (en) 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
CA2587207A1 (en) 2004-11-23 2006-06-01 Merck & Co., Inc. Niacin receptor agonists, compositions containing such compounds and methods of treatment
WO2006060382A2 (en) 2004-11-30 2006-06-08 Trustees Of The University Of Pennsylvania Use of hdac and/or dnmt inhibitors for treatment of ischemic injury
GB0509225D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of enzymatic activity
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
JP2008303145A (en) 2005-09-22 2008-12-18 Takeda Chem Ind Ltd Cardiotonic comprising grk inhibitor
DE102005049385A1 (en) 2005-10-15 2007-04-19 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives as inhibitors of TAFIa
WO2007059533A2 (en) 2005-11-18 2007-05-24 Myogen, Inc. Uses for camki i and hdacs in the treatment of heart conditions
US20070207950A1 (en) 2005-12-21 2007-09-06 Duke University Methods and compositions for regulating HDAC6 activity
WO2008091349A1 (en) 2006-02-14 2008-07-31 The President And Fellows Of Harvard College Bifunctional histone deacetylase inhibitors
WO2008016123A1 (en) 2006-08-03 2008-02-07 Takeda Pharmaceutical Company Limited GSK-3β INHIBITOR
WO2008143647A2 (en) 2006-11-29 2008-11-27 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating viral infection
US20080207704A1 (en) * 2007-02-27 2008-08-28 The Green Cross Corporation Heteroaryl-imidazole derivatives as cannabinoid cb1 receptor antagonists
WO2008140708A1 (en) 2007-05-09 2008-11-20 The Trustees Of The University Of Pennsylvania Use of hdac inhibitors for treatment of cardiac rhythm disorders
CA2701115A1 (en) 2007-10-04 2009-04-09 Merck Sharp & Dohme Corp. N-hydroxy-naphthalene dicarboxamide and n-hydroxy-biphenyl-dicarboxamide compounds as histone deacetylase inhibitors
JP2011502133A (en) 2007-11-02 2011-01-20 メシルジーン インコーポレイテッド Inhibitors of histone deacetylase
DK2291080T3 (en) 2008-05-14 2015-12-07 Scripps Research Inst Novel modulator of sphingosinphosphatreceptorer
EP2307370B1 (en) 2008-06-23 2012-01-04 Basf Se Sulfoximinamide compounds for combating animal pests
WO2010009334A1 (en) 2008-07-17 2010-01-21 Colorado State University Research Foundation Method for preparing largazole analogs and uses thereof
WO2010011296A2 (en) 2008-07-23 2010-01-28 President And Fellows Of Harvard College Deacetylase inhibitors and uses thereof
AU2009303499A1 (en) 2008-10-14 2010-04-22 Oregon Health & Science University Methods for the selection of therapeutic treatments for cancer
EP2393807B1 (en) 2009-02-04 2013-08-14 Boehringer Ingelheim International GmbH Cyclic inhibitors of 11 -hydroxysteroid dehydrogenase 1
US8450363B2 (en) 2009-02-06 2013-05-28 Elan Pharmaceuticals, Inc. Inhibitors of Jun N-terminal kinase
EA201171293A1 (en) 2009-04-24 2012-05-30 Глэксо Груп Лимитед 3-AZABICYCLO [4.1.0] HEPTANS APPLIED AS ANTAGONISTS OF OREXIN
JP2011008205A (en) 2009-05-27 2011-01-13 Fujifilm Corp Composition for producing biaxial optical anisotropic film
EP2438052A1 (en) 2009-06-05 2012-04-11 Oslo University Hospital HF Azole derivatives as wtn pathway inhibitors
US8624040B2 (en) 2009-06-22 2014-01-07 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US9096518B2 (en) 2009-06-22 2015-08-04 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
CA2768466C (en) 2009-07-22 2018-08-14 The Board Of Trustees Of The University Of Illinois Hdac inhibitors and therapeutic methods using the same
CN103492391A (en) 2009-09-25 2014-01-01 沃泰克斯药物股份有限公司 Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
US20120258993A1 (en) 2009-10-21 2012-10-11 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Non-natural macrocyclic amide hdac6 inhibitor compounds and their uses as therapeutic agents
WO2011106627A1 (en) 2010-02-26 2011-09-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2011132048A1 (en) 2010-04-19 2011-10-27 Glenmark Pharmaceutical S.A. Heteroaryl compounds as pde10a inhibitors
WO2011143466A1 (en) 2010-05-12 2011-11-17 Vanderbilt University Heterocyclic sulfone mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US8513421B2 (en) 2010-05-19 2013-08-20 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
CA2800143A1 (en) 2010-05-21 2011-11-24 The Trustees Of Columbia University In The City Of New York Selective hdac inhibitors
US20120015942A1 (en) 2010-07-19 2012-01-19 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2012012322A1 (en) 2010-07-19 2012-01-26 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2012018499A2 (en) 2010-08-05 2012-02-09 Acetylon Pharmaceuticals Specific regulation of cytokine levels by hdac6 inhibitors
WO2012027564A1 (en) 2010-08-26 2012-03-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
EP2625171B1 (en) 2010-10-07 2014-07-30 Basf Se Phenanthro[9,10-b]furans for electronic applications
EP2624832B1 (en) 2010-10-08 2017-09-27 Vib Vzw Hdac inhibitors to treat charcot-marie-tooth disease
WO2012054332A1 (en) 2010-10-18 2012-04-26 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
TW201300380A (en) 2010-10-19 2013-01-01 Comentis Inc Oxadiazole compounds which inhibit beta-secretase activity and methods of use thereof
WO2012066330A1 (en) 2010-11-17 2012-05-24 Heptares Therapeutics Limited Compounds useful as a2a receptor inhibitors
JP2013544874A (en) 2010-12-08 2013-12-19 オスロ ユニヴァーシティー ホスピタル エイチエフ Triazole derivatives as inhibitors of WNT signaling pathway
WO2012106343A2 (en) 2011-02-01 2012-08-09 The Board Of Trustees Of The University Of Illinois Hdac inhibitors and therapeutic methods using the same
ES2602813T3 (en) 2011-06-09 2017-02-22 Rhizen Pharmaceuticals S.A. New compounds as modulators of GPR-119
GB201110546D0 (en) 2011-06-22 2011-08-03 Imp Innovations Ltd Compositions
US9512083B2 (en) 2011-07-20 2016-12-06 The General Hospital Corporation Histone deacetylase 6 selective inhibitors for the treatment of bone disease
WO2013066835A2 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
WO2013066831A1 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2592077A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
JP5966014B2 (en) 2011-11-28 2016-08-10 ノバルティス アーゲー Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of diseases
CN103974956B (en) 2011-11-29 2016-07-06 南京奥昭生物科技有限公司 As HDAC6 inhibitor and the heterocyclic amide being used as antitumor agent
US9409858B2 (en) 2012-03-07 2016-08-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. Selective histone deactylase 6 inhibitors
JP2015515279A (en) 2012-04-19 2015-05-28 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Biomarkers identifying patients who respond to treatment and treatment of such patients
EP2841067A4 (en) 2012-04-25 2016-04-13 Univ California DRUG SCREENING PLATFORM FOR RETT SYNDROME
US9738610B2 (en) 2012-09-24 2017-08-22 Whitehead Institute For Biomedical Research Indazole derivatives and uses thereof
WO2014059306A1 (en) 2012-10-12 2014-04-17 The Trustees Of The University Of Pennsylvania Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
DK2970890T3 (en) 2013-03-14 2020-05-04 Brigham & Womens Hospital Inc COMPOSITIONS AND PROCEDURES FOR THE PROMOTION AND CULTIVATION OF EPITHEL STEM CELLS
EP2976344B1 (en) 2013-03-21 2018-05-16 Universiteit Gent Hdac6 inhibitors and uses thereof
GB201306339D0 (en) 2013-04-08 2013-05-22 Isis Innovation Biomarkers for prognosis
WO2014179144A1 (en) 2013-04-29 2014-11-06 E. I. Du Pont De Nemours And Company Fungicidal heterocyclic compounds
WO2014181137A1 (en) 2013-05-10 2014-11-13 Karus Therapeutics Ltd Novel histone deacetylase inhibitors
WO2014197471A1 (en) 2013-06-03 2014-12-11 Acetylon Pharmaceuticals, Inc. Histone deacetylase ( hdac) biomarkers in multiple myeloma
MX2015017637A (en) 2013-06-17 2016-08-08 Basf Se Substituted pyrimidinium compounds and derivatives for combating animal pests.
WO2015017546A1 (en) 2013-07-30 2015-02-05 H. Lee Moffitt Cancer Center And Research Institute, Inc. Selective histone deactylase 6 inhibitors
US9884806B2 (en) 2013-08-30 2018-02-06 Icahn School Of Medicine At Mount Sinai Cyclic vinylogous amides as bromodomain inhibitors
JP2016531163A (en) 2013-09-20 2016-10-06 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Treatment of diseases caused by abnormal lymphocyte function using HDAC6 inhibitor
KR20160060143A (en) 2013-10-11 2016-05-27 에이스틸론 파마수티컬스 인코포레이티드 Combinations of histone deactylase inhibitors and immunomodulatory drugs
WO2015061684A1 (en) 2013-10-24 2015-04-30 Mayo Foundation For Medical Education And Research Treatment of polycystic diseases with an hdac6 inhibitor
RU2016121868A (en) 2013-11-05 2017-12-08 СИ ЭНД СИ БАЙОФАРМА, ЭлЭлСи TREATMENT OF HEART REMODELING AND OTHER HEART CONDITIONS
CN103613693B (en) 2013-11-29 2015-10-07 中科院广州化学有限公司 The method for making of amphipathic fluoride Nano microsphere/fluorine-containing epoxy resin hybrid and application
WO2015095632A1 (en) 2013-12-20 2015-06-25 Acetylon Pharmaceuticals, Inc. Histone deacetylase 6 (hdac6) biomarkers in multiple myeloma
CA2933907A1 (en) 2013-12-23 2015-07-02 The Trustees Of Columbia University In The City Of New York Selective hdac6 inhibitors
CN106232584B (en) 2014-03-12 2019-06-28 株式会社钟根堂 Novel compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions containing the same
CN106455542A (en) 2014-03-26 2017-02-22 布里格姆及妇女医院股份有限公司 Compositions and methods for ex vivo expansion of human hematopoietic stem/progenitor cells
US10016421B2 (en) 2014-04-05 2018-07-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Histone deacetylase 6 inhibition for enhancing T-cell function during anti-tumor response and tumor-peptide vaccination
US9987258B2 (en) 2014-04-06 2018-06-05 H. Lee Moffitt Cancer Center And Research Institute, Inc. Histone deacetylase as a modulator of PDL1 expression and activity
EP2946788A1 (en) 2014-05-23 2015-11-25 Immundiagnostik AG Method and composition for treating heart failure with preserved ejection fraction
WO2015184279A1 (en) 2014-05-30 2015-12-03 The Johns Hopkins University Compositions and methods for treating kabuki syndrome and related disorders
WO2015187088A1 (en) 2014-06-04 2015-12-10 Thomas Helledays Stiftelse För Medicinsk Forskning Mth1 inhibitors for treatment of cancer
CA2951912A1 (en) 2014-06-12 2015-12-17 University Of Notre Dame Du Lac Composition and method for the treatment of neurological diseases and cerebral injury
CA2952862A1 (en) 2014-06-19 2015-12-23 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr activity
US9668980B2 (en) 2014-07-02 2017-06-06 Rana Therapeutics, Inc. Encapsulation of messenger RNA
US10106540B2 (en) 2014-08-04 2018-10-23 Universität Regensburg HDAC6 inhibitors and their uses
WO2016055786A1 (en) 2014-10-08 2016-04-14 Redx Pharma Plc N-pyridinyl acetamide derivatives as inhibitors of the wnt signalling pathway
CN105801464B (en) 2014-12-29 2019-05-28 成都先导药物开发有限公司 Pyrrole amides class compound and preparation method thereof and purposes
US9993459B2 (en) 2015-01-08 2018-06-12 Universiteit Gent Selective HDAC6 inhibitors and uses thereof
MA41338B1 (en) 2015-01-16 2019-07-31 Hoffmann La Roche Pyrazine compounds for the treatment of infectious diseases
US10183934B2 (en) 2015-02-02 2019-01-22 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
MA42032A (en) 2015-02-02 2018-03-14 Forma Therapeutics Inc 3-ARYL-4-AMIDO-BICYCLO [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS
JP6662917B2 (en) 2015-03-18 2020-03-11 グアンドン・チョンシェン・ファーマスーティカル・カンパニー・リミテッド Histone deacetylase inhibitors and their preparation and use
GB201507340D0 (en) 2015-04-29 2015-06-10 Univ St Andrews Light emitting devices and compounds
HUE051537T2 (en) 2015-07-27 2021-03-01 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same
US10538498B2 (en) * 2015-07-27 2020-01-21 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
KR101799005B1 (en) 2015-07-27 2017-11-17 주식회사 종근당 1,3,4-Oxadiazole Sulfamide Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same
CA2994688C (en) 2015-08-04 2020-11-03 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
GB201514015D0 (en) 2015-08-07 2015-09-23 Arnér Elias S J And Dept Of Health And Human Services Novel pyridazinones and their use in the treatment of cancer
WO2017030892A1 (en) 2015-08-14 2017-02-23 Reaction Biology Corp. Histone deacetylase inhibitors and methods for use thereof
GB201514756D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compound and method of use
KR20180052678A (en) 2015-09-16 2018-05-18 메타크린, 인크. Phenesoid X receptor agonists and uses thereof
US10377717B2 (en) 2015-09-16 2019-08-13 Metacrine, Inc. Farnesoid X receptor agonists and uses thereof
US10696642B2 (en) 2015-09-23 2020-06-30 The General Hospital Corporation TEAD transcription factor autopalmitoylation inhibitors
AU2016338118B2 (en) 2015-10-12 2019-03-14 Chong Kun Dang Pharmaceutical Corp. Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
US10040769B2 (en) 2015-10-27 2018-08-07 Regenacy Pharmaceuticals, Llc HDAC inhibitors for the treatment of diabetic peripheral neuropathy
CA3007025A1 (en) 2015-12-22 2017-06-29 Kancera Ab Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity
WO2017184774A1 (en) 2016-04-19 2017-10-26 Acetylon Pharmaceuticals, Inc. Hdac inhibitors, alone or in combination with btk inhibitors, for treating chronic lymphocytic leukemia
TW201808914A (en) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 Modulators of the integrated stress pathway
WO2017222950A1 (en) * 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3-heterocyclyl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
WO2017222951A1 (en) * 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
WO2018029602A1 (en) 2016-08-08 2018-02-15 Hetero Labs Limited C-3 novel triterpenone with c-28 heterocycle derivatives as hiv inhibitors
US20190192521A1 (en) 2016-08-15 2019-06-27 The Wistar Institute Of Anatomy And Biology Methods of Treating Arid1A-Mutated Cancers With HDAC6 Inhibitors and EZH2 Inhibitors
JP7542947B2 (en) 2016-10-28 2024-09-02 アセチロン ファーマシューティカルズ インコーポレイテッド Pharmaceutical combinations including histone deacetylase inhibitors and epothilones and methods of use thereof
JP7282674B2 (en) 2016-10-28 2023-05-29 アセチロン ファーマシューティカルズ インコーポレイテッド Pharmaceutical combinations comprising a histone deacetylase inhibitor and an Aurora kinase inhibitor and methods of use thereof
SI3535275T1 (en) 2016-11-04 2022-10-28 Acetylon Pharmaceuticals, Inc. Pharmaceutical combinations comprising a histone deacetylase inhibitor and a bcl-2 inhibitor and methods of use thereof
WO2018089651A1 (en) 2016-11-10 2018-05-17 Acetylon Pharmaceuticals, Inc. Phenyl and pyridinyl hydroxamic acids
JP7516047B2 (en) 2016-11-23 2024-07-16 アセチロン ファーマシューティカルズ インコーポレイテッド Pharmaceutical combinations comprising histone deacetylase inhibitors and cd38 inhibitors and methods of use thereof
EP3544600A4 (en) 2016-11-23 2020-06-17 Acetylon Pharmaceuticals, Inc. PHARMACEUTICAL COMBINATIONS WITH A HISTONE DEACETYLAS INHIBITOR AND A PROGRAMMED DEATH LIGAND-1 (PD-L1) INHIBITOR AND METHOD FOR USE THEREOF
EP4046989A1 (en) 2017-01-09 2022-08-24 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
AU2018208160B2 (en) 2017-01-10 2021-03-04 Cstone Pharmaceuticals HDAC6 selective inhibitors, preparation method therefor, and application thereof
WO2018154118A2 (en) 2017-02-24 2018-08-30 Reinmueller Viktoria Novel aromatic compounds
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
AU2018250599B2 (en) 2017-04-11 2022-05-26 The General Hospital Corporation HDAC6 inhibitors and imaging agents
TWI791527B (en) 2017-06-01 2023-02-11 美商必治妥美雅史谷比公司 Substituted nitrogen containing compounds
EP3424925A1 (en) 2017-07-06 2019-01-09 Universität Regensburg Novel hdac6 inhibitors, with improved solubility and their uses
IT201700086293A1 (en) 2017-07-27 2019-01-27 St Oncologico Veneto Iov Irccs INHIBITORS OF HISTONE DEACETILASE 6 FOR THE TREATMENT OF ACUTE T-T (T-ALL) AND OTHER NEOPLASIES WITH HIGH NOTCH3 EXPRESSION
JP7135007B2 (en) * 2017-07-31 2022-09-12 武田薬品工業株式会社 heterocyclic compound
US20200216563A1 (en) 2017-08-10 2020-07-09 Friedrich Miescher Institute For Biomedical Research Hdac6 and protein aggregation
JP6878225B2 (en) 2017-09-15 2021-05-26 デクセリアルズ株式会社 Manufacturing method of transparent panel, manufacturing method of optical device
KR102832035B1 (en) 2017-09-29 2025-07-09 인텔리아 테라퓨틱스, 인크. In vitro method of mRNA delivery using lipid nanoparticles
EP3473618A1 (en) 2017-10-17 2019-04-24 Centre National De La Recherche Scientifique 6-substituted 3-fluoro-2-pyridinaldoxime, 3-fluoro-2-pyridine hydroxamic acid, and 3-fluoro-2-pyridinamidoxime scaffolds
US20190216751A1 (en) 2017-11-15 2019-07-18 California State University Northridge Compositions and Methods for the Treatment and Prevention of Cancer
CN111587249A (en) 2017-11-20 2020-08-25 阿里根公司 Indole compounds and uses thereof
BR112020010534A2 (en) 2017-12-05 2020-10-20 Oryzon Genomics, S.A. 1,2,4-oxadiazole derivatives as histone deacetylase 6 inhibitors
US11040945B2 (en) 2017-12-06 2021-06-22 Lin Bioscience Pty Ltd. Tubulin inhibitors
EP3724188B1 (en) 2017-12-12 2023-06-07 Arkuda Therapeutics Progranulin modulators and methods of using the same
US11407723B2 (en) 2018-01-09 2022-08-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
KR102059027B1 (en) 2018-01-12 2019-12-24 주식회사 비엔에이치리서치 Pharmaceutical Composition Comprising Inhibitor of HDAC6 for Preventing or Treating Itch
US20210009541A1 (en) 2018-02-12 2021-01-14 Bayer Aktiengesellschaft Fungicidal oxadiazoles
WO2019169267A1 (en) 2018-03-01 2019-09-06 Reaction Biology Corp. Quinoline and isoquinoline based hdac inhibitors and methods of use thereof
US11155550B2 (en) 2018-03-01 2021-10-26 Reaction Biology Corporation Histone deacetylase inhibitors and methods of use thereof
EP3762367A1 (en) 2018-03-09 2021-01-13 PI Industries Ltd. Heterocyclic compounds as fungicides
WO2019173790A1 (en) 2018-03-09 2019-09-12 Timothy Hla Pyridinone- and pyridazinone-based compounds and medical uses thereof
MA52489A (en) 2018-05-04 2021-03-10 Inflazome Ltd NEW COMPOUNDS
US20200016274A1 (en) 2018-05-30 2020-01-16 Translate Bio, Inc. Messenger rna vaccines and uses thereof
US11045458B2 (en) 2018-07-23 2021-06-29 Wisconsin Alumni Research Foundation Synthesis of small molecule histone deacetylase 6 degraders, compounds formed thereby, and pharmaceutical compositions containing them
KR102316234B1 (en) 2018-07-26 2021-10-22 주식회사 종근당 1,3,4-Oxadiazole Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same
KR102660255B1 (en) 2018-08-13 2024-04-25 길리애드 사이언시즈, 인코포레이티드 Pyrrolo[1,2-B]pyridazine derivatives as IRAK4 inhibitors
AU2019323712A1 (en) 2018-08-24 2021-02-25 Xeniopro GmbH Aromatic molecules for use in the treatment of pathological conditions
US20220016265A1 (en) 2018-11-09 2022-01-20 Translate Bio, Inc. Messenger rna therapy for treatment of ocular diseases
JP7707073B2 (en) 2019-04-09 2025-07-14 エフ． ホフマン－ラ ロシュ アーゲー Heterocyclic Compounds as Inhibitors of Monoacylglycerol Lipase (MAGL)
KR20220016918A (en) 2019-06-04 2022-02-10 하거 바이오사이언시즈, 엘엘씨 Imidazolo derivatives, compositions and methods as orexin antagonists
JP2022534709A (en) 2019-06-04 2022-08-03 ヘイガー バイオサイエンシズ，エルエルシー Pyrazole and Imidazole Derivatives, Compositions, and Methods as Orexin Antagonists
CA3151516A1 (en) 2019-09-12 2021-03-18 F. Hoffmann-La Roche Ag 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors
DK4031547T3 (en) 2019-09-18 2024-09-09 Takeda Pharmaceuticals Co PLASMA KALLIKREIN INHIBITORS AND USES THEREOF
BR112022005595A2 (en) 2019-09-27 2022-07-19 Takeda Pharmaceuticals Co COMPOUND, DRUG, METHODS FOR INHIBITING HISTONE DEACETYLASE 6 AND FOR PROPHYLAXIS OR TREATMENT OF ALZHEIMER'S DISEASE OR PROGRESSIVE SUPRANUCLEAR PALSY IN A MAMMAL, AND, COMPOUND USE
WO2021067859A1 (en) 2019-10-03 2021-04-08 Tenaya Therapeutics, Inc. 5-fluoronicotinamide derivatives and uses thereof
AU2020369593A1 (en) 2019-10-23 2022-05-19 Case Western Reserve University Method of modulating ribonucleotide reductase
WO2021113401A2 (en) 2019-12-02 2021-06-10 The Regents Of The University Of Colorado, A Body Corporate Histone deacytlase 6 modulation of titin protein mediated cardiac tissue stiffness and method for same
KR20220119653A (en) 2019-12-20 2022-08-30 테나야 테라퓨틱스, 인코포레이티드 Fluoroalkyl-oxadiazoles and uses thereof
EP4117663A4 (en) 2020-03-12 2024-07-03 3+2 Pharma LLC INHIBITORS OF THE CBP/CATENIN SIGNALING PATHWAY AND THEIR USES
WO2021185256A1 (en) 2020-03-16 2021-09-23 上海海雁医药科技有限公司 Substituted pyrimidine or pyridine amine derivative, composition thereof, and medical use thereof
CN115916752B (en) 2020-06-26 2025-05-06 日本农药株式会社 Aryltetrahydropyridine derivatives or their salts, insecticides containing the same and methods of use thereof
CA3186902A1 (en) 2020-06-26 2021-12-30 Nihon Nohyaku Co., Ltd. Aryltetrahydropyridazine derivative or salt thereof, insecticidal agent containing the compound, and method of use thereof
AR123264A1 (en) 2020-08-18 2022-11-16 Pi Industries Ltd NEW HETEROCYCLIC COMPOUNDS TO COMBAT PHYTOPATHOGENIC FUNGI
EP4497473A3 (en) 2020-08-26 2025-04-23 Haisco Pharmaceuticals Pte. Ltd. Nitrile derivative that acts as inhibitor of dipeptidyl peptidase 1 and use thereof
CN112794860B (en) 2021-03-24 2021-06-29 上海肇钰医药科技有限公司 Oxazole pyrimidone amide compound or medicinal salt thereof, preparation method and application
US20240269137A1 (en) 2021-04-23 2024-08-15 Tenaya Therapeutics, Inc. Hdac6 inhibitors for treatment of dilated cardiomyopathy
MX2023012875A (en) 2021-05-04 2024-01-12 Tenaya Therapeutics Inc 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef.

Also Published As

Publication number Publication date
WO2022235842A1 (en) 2022-11-10
TW202308619A (en) 2023-03-01
IL308152A (en) 2024-01-01
EP4333841A1 (en) 2024-03-13
JP2024519499A (en) 2024-05-14
US20240252502A1 (en) 2024-08-01
US12201617B2 (en) 2025-01-21
KR20240016950A (en) 2024-02-06
CA3216768A1 (en) 2022-11-10
US20230381148A1 (en) 2023-11-30
AU2022270657A1 (en) 2023-11-16

Similar Documents

Publication Publication Date Title
MX2023012875A (en) 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef.
MX2022011804A (en) Use of agents for treatment of respiratory conditions.
MX2023012095A (en) Hdac6 inhibitors for use in the treatment of dilated cardiomyopathy.
AR044007A1 (en) METHODS FOR THE TREATMENT OF PARKINSON&#39;S DISEASE
AR119158A1 (en) HEREDITARY ANGIOEDEMA TREATMENTS
AR075423A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING AN SGLT-2 INHIBITOR, PHARMACEUTICAL FORM, PROCEDURE FOR PREPARATION, TREATMENT METHODS AND ITS USES
EP4487908A3 (en) Methods of treating crohn&#39;s disease and ulcerative colitis
EP4424328A3 (en) Treatment of hidradenitis suppurativa using jak inhibitors
FI4243825T3 (en) Omecamtiv mecarbil for the treatment of heart failure in selected patient groups
BRPI0414455A (en) Methods for Using Regenerative Cells to Treat Peripheral Vascular Disease and Related Disorders
NZ600718A (en) Method of treating atrial fibrillation
MX2024008461A (en) Methods of treating malignant lymphoproliferative disorders.
BR112023021131A2 (en) ESSENTIAL TREMOR TREATMENT
Giraud et al. The LUCAS 2 chest compression device is not always efficient: an echographic confirmation
ZA202210079B (en) Compositions and methods for treating or preventing inflammatory diseases including diabetes mellitus 10 type i and type ii and thyroid diseases
AR119159A1 (en) ANGIOEDEMA TREATMENTS
PE20241327A1 (en) TREATMENT OF LIVER DISORDERS WITH A THR-BETA AGONIST
AU2021322255A8 (en) Use of dexpramipexole for the treatment of moderate to severe asthma
WO2022047128A3 (en) Method for treating complement mediated disorders caused by betacoronaviruses
MX2021003681A (en) Benzimidazole derivative for use in the treatment of inflammatory disorders.
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
SG156681A1 (en) Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure
MX2022016406A (en) METHODS FOR TREATING CANCER OR VON-HIPPEL LINDAU DISEASE USING A COMBINATION OF A HIF-2 ALPHA INHIBITOR AND LENVATINIB.
WO2019139956A3 (en) Prevention and treatment of organ fibrosis
WO2021242844A8 (en) Grk2 inhibitors and uses thereof